Quick Nav
Publications
Pharmacy Times
News Briefs

MEDICAID TO REVISE AMP REIMBURSEMENT FOR GENERICS

Published Online: Saturday, July 1, 2006   [ Request Print ]

Incentives built into the new Medicare Part D drug plan to increase the use of generic drugs are driving down program costs significantly, according to the results of a new study. Researchers at Verispan found that 55% of all prescriptions being filled by Medicare patients during the first 3 months of the new program were for generic drugs.

Teva Pharmaceuticals was the leading supplier of drugs for Medicare recipients enrolled in Part D. Four other generic manufacturers—Mylan Pharmaceuticals, Watson Pharmaceuticals Inc, IVAX Pharmaceuticals Inc, and Mallinckrodt Medical—also ranked among the top 10, the researchers said.


Related Articles
No Result Found




Intellisphere, LLC
666 Plainsboro Road
Building 300
Plainsboro, NJ 08536
P: 609-716-7777
F: 609-257-0701

Copyright HCPLive 2006-2013
Intellisphere, LLC. All Rights Reserved.
 




Become a Member
Forgot Password?